Zanidatamab, a human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody, is suitable for advanced, unresectable, and metastatic HER2-expressing biliary tract cancers [3]. Here, ERBB2 is linked to biliary tract neoplasm.